Steven Seedhouse
Stock Analyst at Raymond James
(3.40)
# 966
Out of 4,711 analysts
162
Total ratings
43.31%
Success rate
4.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $3.59 | +512.81% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $23.80 | +135.29% | 3 | Nov 8, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $53 → $49 | $7.94 | +517.13% | 10 | Nov 8, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $2.63 | +432.32% | 6 | Oct 29, 2024 | |
| KRRO Korro Bio | Initiates: Strong Buy | $153 | $43.67 | +250.35% | 1 | Oct 21, 2024 | |
| WVE Wave Life Sciences | Upgrades: Strong Buy | $13 → $22 | $13.51 | +62.84% | 2 | Oct 16, 2024 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $116 → $118 | $42.25 | +179.29% | 17 | Jul 25, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $93 | $92.57 | +0.46% | 9 | Jul 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Strong Buy | $57 → $68 | $42.60 | +59.62% | 3 | May 10, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $33.21 | +219.18% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $4.82 | +211.20% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $23.99 | +133.43% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $41.51 | +54.18% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $2.91 | +501.37% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $12.18 | +367.98% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $21 → $19 | $2.24 | +748.21% | 13 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $2.28 | +864.91% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.31 | +1,197.71% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $11.56 | +202.77% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $40.66 | -6.54% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $31.82 | +123.13% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.84 | +495.24% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $14.55 | +161.17% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $15.48 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.05 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $146.47 | - | 2 | Apr 23, 2020 |
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $3.59
Upside: +512.81%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $23.80
Upside: +135.29%
89bio
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $7.94
Upside: +517.13%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.63
Upside: +432.32%
Korro Bio
Oct 21, 2024
Initiates: Strong Buy
Price Target: $153
Current: $43.67
Upside: +250.35%
Wave Life Sciences
Oct 16, 2024
Upgrades: Strong Buy
Price Target: $13 → $22
Current: $13.51
Upside: +62.84%
Viking Therapeutics
Jul 25, 2024
Maintains: Strong Buy
Price Target: $116 → $118
Current: $42.25
Upside: +179.29%
Gilead Sciences
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $92.57
Upside: +0.46%
Vera Therapeutics
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $42.60
Upside: +59.62%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $33.21
Upside: +219.18%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $4.82
Upside: +211.20%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $23.99
Upside: +133.43%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $41.51
Upside: +54.18%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $2.91
Upside: +501.37%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $12.18
Upside: +367.98%
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $2.24
Upside: +748.21%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $2.28
Upside: +864.91%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.31
Upside: +1,197.71%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $11.56
Upside: +202.77%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $40.66
Upside: -6.54%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $31.82
Upside: +123.13%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.84
Upside: +495.24%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $14.55
Upside: +161.17%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $15.48
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.05
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $146.47
Upside: -